Fleur Van Der Sijde
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 13, 2023
Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries-Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients.
Journal: Cancers
Published: June 28, 2023
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 22, 2022
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
Journal: Frontiers in immunology
Published: March 18, 2022
Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study.
Journal: Journal of oncology
Published: March 07, 2022
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
Journal: International journal of molecular sciences
Published: September 09, 2021
Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: July 09, 2021
Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 11, 2021
Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.
Journal: Therapeutic advances in medical oncology
Published: February 11, 2021
Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer.
Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association
Published: October 23, 2020
RNA from stabilized whole blood enables more comprehensive immune gene expression profiling compared to RNA from peripheral blood mononuclear cells.
Journal: PloS one
Published: March 06, 2020
Last Updated: 09/26/2026